BackZhejiang Shouxiangu Pharmaceutical , Ltd. Overview

Zhejiang Shouxiangu Pharmaceutical , Ltd. Inventory

Latest inventory for 603896.SS: $240M.

Get informed when a big investor buys or sells

+ Follow
Inventory
$244.59M
↑ 8.72% YoYΔ $19.61M vs prior year quarter

Peer trimmed avg / median

Loading

Zhejiang Shouxiangu Pharmaceutical , Ltd. Inventory History

Loading

Zhejiang Shouxiangu Pharmaceutical , Ltd. vs. peers: Inventory Comparison

Loading

Zhejiang Shouxiangu Pharmaceutical , Ltd. Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Zhejiang Shouxiangu Pharmaceutical , Ltd. (603896.SS) FAQ

Zhejiang Shouxiangu Pharmaceutical , Ltd.'s inventory stands at $240M as of June 2026. That compares with $220M in the prior-year period — up 8.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Zhejiang Shouxiangu Pharmaceutical , Ltd. reported $240M in inventory versus $220M a year earlier — a 8.7% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $220M in the prior-year period — up 8.7% year over year. Sustained growth in inventory can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Zhejiang Shouxiangu Pharmaceutical , Ltd.'s inventory evolved across reporting periods, while the comparison chart places 603896.SS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, inventory is commonly used to spot outliers. Zhejiang Shouxiangu Pharmaceutical , Ltd.'s reading of $240M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.